Increasing resistance among Gram-negative uropathogens limits treatment options, and susceptibility data for multidrug-resistant isolates are limited. We assessed the activity of five oral agents against 91 multidrug-resistant Gram-negative urine isolates that were collected from emergency department/hospitalized patients. Fosfomycin and nitrofurantoin were most active (>75% susceptibility). Susceptibilities to sulfamethoxazole-trimethoprim, ciprofloxacin, and ampicillin were <40%; empirical use of these agents likely provides inadequate coverage in areas with a high prevalence of multidrug-resistant uropathogens.
M
ultidrug resistance among Gram-negative bacilli that cause uncomplicated urinary tract infections (UTIs), such as Pseudomonas aeruginosa and Klebsiella pneumoniae, is increasing (1, 2) . Such resistance significantly limits patient treatment options (3) (4) (5) (6) . There is a paucity of published data on current in vitro susceptibility profiles for multidrug-resistant (MDR) urine isolates (7, 8) . As UTIs are commonly treated in the outpatient setting with oral agents, knowledge of susceptibility patterns in MDR urinary pathogens is critical to guide empirical treatment (9) . We therefore assessed the in vitro activity of five oral agents-fosfomycin, nitrofurantoin, sulfamethoxazole-trimethoprim, ciprofloxacin, and ampicillin-against 91 MDR Gram-negative urine isolates.
(This research was presented in part at the 25th European Congress of Clinical Microbiology and Infectious Diseases, Copenhagen, Denmark, 25 to 28 April 2015.)
Consecutive, nonduplicate monomicrobial urine cultures of Enterobacteriaceae and Pseudomonas aeruginosa from hospitalized or emergency department (ED) patients were collected between August 2013 and January 2014 from the Beth Israel Deaconess Medical Center (BIDMC) clinical microbiology laboratory as previously described (10) . All isolates were collected from unique patients, and those from non-ED outpatient locations were excluded. Only MDR isolates, defined as nonsusceptible to Ն1 agent in at least 3 antibiotic classes, were assessed during the study period (11) . BIDMC is a 649-bed level 1 trauma center and teaching hospital affiliated with Harvard Medical School. The study was approved by the Institutional Review Boards at BIDMC and Northeastern University.
For further characterization of isolates meeting study criteria, those nonsusceptible to carbapenems and third/fourth-generation cephalosporins were screened for extended-spectrum ␤-lactamase (ESBL) production using double-disk testing with cefotaxime (30 g) and ceftazidime (30 g) alone and in combination with clavulanate (10 g) as recommended by the Clinical and Laboratory Standards Institute (CLSI) (12) . Isolates that were nonsusceptible to carbapenems were screened for the presence of bla KPC and bla NDM by PCR and gene sequencing (13, 14) .
Antibiotic susceptibility was determined by several methods. Fosfomycin and nitrofurantoin MICs were determined in duplicate on separate days by agar dilution as previously described (10) . Ciprofloxacin, sulfamethoxazole-trimethoprim, and ampicillin MICs were determined by automated susceptibility testing (Vitek 2). CLSI M100-S24 interpretive criteria for Enterobacteriaceae were utilized for all antimicrobials. For fosfomycin, breakpoints were Յ64 g/ml (susceptible), 128 g/ml (intermediate), and Ն256 g/ml (resistant). For nitrofurantoin, breakpoints were Յ32 g/ml (susceptible), 64 g/ml (intermediate), and Ն128 g/ml (resistant). For sulfamethoxazole-trimethoprim, break- crossmark points were Յ2/38 g/ml (susceptible) and Ն4/76 g/ml (resistant). For ampicillin, breakpoints were Յ8 g/ml (susceptible), 16 g/ml (intermediate), and Ն32 g/ml (resistant). Lastly, the ciprofloxacin breakpoints that were used were applicable for Enterobacteriaceae and P. aeruginosa (Յ1 g/ml, susceptible; 2 g/ml, intermediate; Ն4 g/ml, resistant) (12) . Agent-specific susceptibility results for species with intrinsic resistance to nitrofurantoin (Morganella spp., Proteus spp., P. aeruginosa), ampicillin (all species other than Escherichia coli and Proteus mirabilis), or sulfamethoxazole-trimethoprim (P. aeruginosa) were not included in susceptibility analyses.
Of the 258 Gram-negative isolates that were collected during the study period, 91 (35.3%) were considered MDR and were selected for further study. They consisted of E. coli (n ϭ 66), P. aeruginosa (n ϭ 9), Klebsiella spp. (n ϭ 8), P. mirabilis (n ϭ 5), Enterobacter cloacae (n ϭ 2), and Morganella morganii (n ϭ 1). Forty-nine (53.8%) isolates were collected from inpatients, while 42 (46.2%) were collected from patients in the emergency department. Overall susceptibility for the isolates is presented in Table 1 . Notably, 29 isolates (31.9%) were nonsusceptible to 3 classes of agents, 24 (26.4%) were nonsusceptible to 4 classes of agents, 14 (15.4%) were nonsusceptible to 5 classes, and the remaining 24 (26.4%) were nonsusceptible to Ն6 classes. Fosfomycin displayed the most consistent activity (94.5% susceptibility) followed by nitrofurantoin (85.6% susceptibility), whereas ampicillin was the least active.
MIC distributions by species are shown in Table 2 . MIC 50/90 values and ranges were calculated for fosfomycin and nitrofurantoin. As automated susceptibility testing was used for sulfamethoxazole-trimethoprim, ciprofloxacin, and ampicillin with a limited range of MIC values reported, MIC 50/90 distributions could not be calculated.
Thirty (33%) isolates were confirmed as ESBL producers by double-disk confirmatory testing (22 E. coli, 7 Klebsiella spp., and 1 E. cloacae). One ESBL E. coli also harbored the KPC-3 variant (excluded from ESBL analyses, Tables 1 and 2 ). Susceptibilities by ESBL status are presented in Table 1 . Of note, ESBL-producing isolates retained almost equivalent susceptibility to fosfomycin, sulfamethoxazole-trimethoprim, and nitrofurantoin, while susceptibilities to ciprofloxacin were markedly decreased compared to the full (n ϭ 91) collection.
Fosfomycin is currently recommended as a first-line agent for uncomplicated UTI and was the most active oral agent against this collection of MDR and/or ESBL-confirmed isolates (15) . Notably, these isolates were collected from either hospitalized or ED patients; therefore, it could be presumed that a number of these isolates may have been responsible for complicated UTIs among this population. Recommended methods for fosfomycin susceptibility testing (agar dilution/disk diffusion) are time-consuming and limit its routine testing among clinical microbiology laboratories (10) . Our data suggest that fosfomycin may be a useful agent for avoiding broad-spectrum intravenous treatment of UTI for patients with risk of MDR uropathogens. Recent susceptibility data specific to MDR uropathogens are limited. Sanchez et al. recently reported on susceptibilities of outpatient E. coli isolates to 6 different agents in the United States (9). Fosfomycin was not tested. However, among isolates with resistance to 3 (n ϭ 3,556), 4 (n ϭ 1,506), or 5 (n ϭ 439) out of 6 drug classes examined, nitrofurantoin susceptibilities were high at 97.9%, 92.5%, and 75.9%, respectively, and ciprofloxacin susceptibilities were much lower at 51.1%, 15.7%, and 1.8%, respectively, which is similar to the trends observed in our data set.
Among our collection of 91 MDR urine isolates, fosfomycin was consistently active (using the breakpoint of 64 g/ml), while susceptibilities to sulfamethoxazole-trimethoprim, ciprofloxacin, and ampicillin were Յ40%. In patients with risk factors for MDR UTI or in areas with high prevalence of MDR urine isolates, empirical use of the latter agents likely provides inadequate coverage of UTI, and alternative use of fosfomycin or nitrofurantoin should be considered either initially or if there is inadequate response to therapy.
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